Guggenheim raised the firm’s price target on Guardant Health (GH) to $135 from $115 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
- Leerink sees Court ruling as small win for Guardant, no change to patent risk
- Guardant Health receives FDA approval for Guardant360 CDx in colorectal cancer
- Guardant Health announces multi-year strategic agreement with Merck
- Guardant Health Announces Strong 2025 Preliminary Revenue Growth